The role of pharmacists in providing counselling as well as drugs to smokers wanting to quit could be in for a boost following results of a new study.
An article in the latest issue of the Annals of Internal Medicine concluded that patients were more likely to abstain from smoking when they combined pharmacotherapy with disease management such as counselling and provider feedback.
A third of the 750 patients taking part in the two-year study only relied on therapy with nicotine patches or bupropion, marketed in Australia as Clorprax, Prexaton or Zyban.
Meanwhile, the other two thirds also received either "high-intensity" management of up to six counselling sessions or two "moderate-intensity" counselling sessions.
"Abstinence rates increased throughout the study, and overall analyses demonstrated higher...
This site is intended for Registered Medical Practitioners.
To make the most of Pharmacy News, you need to be logged in.